File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term study of mycophenolate mofetil treatment in IgA nephropathy

TitleLong-term study of mycophenolate mofetil treatment in IgA nephropathy
Authors
KeywordsIgA nephropathy
Mycophenolate
Proteinuria
Remission
Renal survival
Issue Date2010
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ki/index.html
Citation
Kidney International, 2010, v. 77 n. 6, p. 543-549 How to Cite?
AbstractSince the efficacy of mycophenolate mofetil (MMF) to treat immunoglobulin A (IgA) nephropathy is controversial, we extended our original study by following 40 Chinese patients with established IgA nephropathy for 6 years. All patients were maintained on their angiotensin blockade medication and half were randomized to receive MMF for 6 months. After 6 years, 11 patients required dialysis (2 from the MMF and 9 from the control group). Significantly, only 3 treated (as compared to 10 control) patients reached the composite end point of serum creatinine doubling or end-stage renal disease. Linear regression showed the annualized decline in the estimated glomerular filtration rate was significantly less in the MMF-treated group. Urinary protein excretion and the albumin-to-creatinine ratio were lower with MMF treatment during the first 24 months, beyond which there was no difference between groups. Multivariable Cox regression analysis showed that the baseline estimated glomerular filtration rate and proteinuria, and change in the urine albumin-to-creatinine ratio at 1 year to be important predictors of progression to end-stage renal disease. We found that among Chinese patients with IgA nephropathy who had mild histologic lesions and persistent proteinuria despite maximal angiotensin blockade, MMF treatment may result in transient and partial remission of proteinuria in the short-term and renoprotection in the long-term. © 2010 International Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/137100
ISSN
2015 Impact Factor: 7.683
2015 SCImago Journal Rankings: 3.181
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong Society of Nephrology
Funding Information:

This work was supported in part by the Hong Kong Society of Nephrology Research Grant 2002. Roche Pharmaceuticals supplied the MMF used in this study. We are grateful to Ms Sandra Luen for clerical support.

References

 

DC FieldValueLanguage
dc.contributor.authorTang, SCWen_HK
dc.contributor.authorTang, AWCen_HK
dc.contributor.authorWong, SSHen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorHo, YWen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2011-08-16T02:14:24Z-
dc.date.available2011-08-16T02:14:24Z-
dc.date.issued2010en_HK
dc.identifier.citationKidney International, 2010, v. 77 n. 6, p. 543-549en_HK
dc.identifier.issn0085-2538en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137100-
dc.description.abstractSince the efficacy of mycophenolate mofetil (MMF) to treat immunoglobulin A (IgA) nephropathy is controversial, we extended our original study by following 40 Chinese patients with established IgA nephropathy for 6 years. All patients were maintained on their angiotensin blockade medication and half were randomized to receive MMF for 6 months. After 6 years, 11 patients required dialysis (2 from the MMF and 9 from the control group). Significantly, only 3 treated (as compared to 10 control) patients reached the composite end point of serum creatinine doubling or end-stage renal disease. Linear regression showed the annualized decline in the estimated glomerular filtration rate was significantly less in the MMF-treated group. Urinary protein excretion and the albumin-to-creatinine ratio were lower with MMF treatment during the first 24 months, beyond which there was no difference between groups. Multivariable Cox regression analysis showed that the baseline estimated glomerular filtration rate and proteinuria, and change in the urine albumin-to-creatinine ratio at 1 year to be important predictors of progression to end-stage renal disease. We found that among Chinese patients with IgA nephropathy who had mild histologic lesions and persistent proteinuria despite maximal angiotensin blockade, MMF treatment may result in transient and partial remission of proteinuria in the short-term and renoprotection in the long-term. © 2010 International Society of Nephrology.en_HK
dc.languageeng-
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ki/index.htmlen_HK
dc.relation.ispartofKidney Internationalen_HK
dc.subjectIgA nephropathyen_HK
dc.subjectMycophenolateen_HK
dc.subjectProteinuriaen_HK
dc.subjectRemissionen_HK
dc.subjectRenal survivalen_HK
dc.subject.meshAdulten_HK
dc.subject.meshCreatinine - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGlomerular Filtration Rateen_HK
dc.subject.meshGlomerulonephritis, IGA - blood - drug therapy - physiopathologyen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunosuppressive Agents - therapeutic useen_HK
dc.subject.meshKidney Failure, Chronic - prevention & controlen_HK
dc.subject.meshLongitudinal Studiesen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMycophenolic Acid - analogs & derivatives - therapeutic useen_HK
dc.subject.meshProteinuria - drug therapyen_HK
dc.subject.meshRemission Induction - methodsen_HK
dc.titleLong-term study of mycophenolate mofetil treatment in IgA nephropathyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0085-2538&volume=77&issue=6&spage=543&epage=549&date=2010&atitle=Long-term+study+of+mycophenolate+mofetil+treatment+in+IgA+nephropathy-
dc.identifier.emailTang, SCW: scwtang@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityTang, SCW=rp00480en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/ki.2009.499en_HK
dc.identifier.pmid20032964-
dc.identifier.scopuseid_2-s2.0-77949542202en_HK
dc.identifier.hkuros173980-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77949542202&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume77en_HK
dc.identifier.issue6en_HK
dc.identifier.spage543en_HK
dc.identifier.epage549en_HK
dc.identifier.eissn1523-1755-
dc.identifier.isiWOS:000274996700012-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.f10002809958-
dc.identifier.scopusauthoridTang, SCW=7403437082en_HK
dc.identifier.scopusauthoridTang, AWC=7201845919en_HK
dc.identifier.scopusauthoridWong, SSH=35785406900en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridHo, YW=7402555047en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.citeulike6602172-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats